Get started
Author

Hock Choong Lai

Observed names: H. C. Lai, Hock C. Lai, Hock Lai, Hock-Choong Lai
Institution: Townsville Hospital
ORCID: 0009-0002-7008-6850
Observed ORCID: 0009-0002-7008-6850
OpenAlex ID: A5103852522
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
2025 · Lorenzo Falchi, Marcel Nijland, et al. · The Lancet · 50
Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials
2016 · Minnie Au, Theophilus Emeto, et al. · Biomedicines · 36
PDF
Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol
2014 · Jay Hocking, Anthony P. Schwarer, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 25
A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia
2019 · Karthik Nath, Vibooshini Ganeshalingam, et al. · Supportive Care in Cancer · 21
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
2025 · Attaya Suvannasankha, Jonathan Kaufman, et al. · Blood · 11
PDF
Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry
2020 · Yadanar Lwin, Glenn Kennedy, et al. · Transplantation and Cellular Therapy · 9
Australia and New Zealand Transplant and Cellular Therapies COVID‐19 vaccination consensus position statement
2021 · Nada Hamad, Michelle Ananda‐Rajah, et al. · Internal Medicine Journal · 8
PDF
Isolated intracranial myeloid sarcoma
2012 · Georgina Hodges, Hock Choong Lai, et al. · Pathology · 6
A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.
2021 · Hang Quach, Masa Lasica, et al. · Journal of Clinical Oncology · 5
Bone Marrow Transplant Society of Australia and New Zealand COVID‐19 consensus position statement
2020 · Nada Hamad, David Gottlieb, et al. · Internal Medicine Journal · 5
PDF
Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
2020 · Georgia J McCaughan, Steven Tran, et al. · Blood · 4
A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience
2019 · Elizabeth M. Hamilton, Karthik D. Nath, et al. · Internal Medicine Journal · 4
Screening whole spine magnetic resonance imaging in multiple myeloma
2015 · J. Wight, A. Stillwell, et al. · Internal Medicine Journal · 4
Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)
2025 · Matthew Rees, Masa Lasica, et al. · Blood · 3
PDF
A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study
2023 · Masa Lasica, Andrew Spencer, et al. · Blood · 3
Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)
2023 · Hang Quach, Masa Lasica, et al. · Blood · 3
PDF
An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation
2020 · Kirsty M Sharplin, David Ritchie, et al. · Blood · 2
High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission
2020 · Matthew J. Rees, Andrew Spencer, et al. · Bone Marrow Transplantation · 2
A comprehensive study of the epidemiology of haematological malignancies in North Queensland
2021 · Karthik Nath, Rachael Boles, et al. · Internal Medicine Journal · 1
PDF
Trends and Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
2021 · Georgia Jane McCaughan, Steven Tran, et al. · Transplantation and Cellular Therapy · 1
An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era
2019 · Yadanar Lwin, Simon Zhao-Xiong He, et al. · Blood · 1
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 ( SeaLAND ) trial
2026 · Matthew J. Rees, Masa Lasica, et al. · British Journal of Haematology
PDF
A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Mm): Primary Analysis. Amarc 19-02 Belacard Study
2025 · Masa Lasica, Andrew Spencer, et al. · Clinical Lymphoma Myeloma & Leukemia
Rural/Regional Place of Residence Impacts Post Allogeneic Bone Marrow Transplant Overall Survival of Australian Patients with Acute Myeloid Leukaemia: An Anztct Registry Study
2024 · Zulekha Khan, Glen A Kennedy, et al. · Blood
PDF
P-313 ALLG MM25 (VIBER-M): a phase Ib/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14)
2023 · Shirlene Sim, Ann Solterbeck, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 30
Citation count: 204
H-index: 7
I10-index: 5
Year
Topic
Type